Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
164 participants
INTERVENTIONAL
2020-06-01
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Ivermectin in COVID-19
NCT05076253
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
NCT04739410
The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19
NCT04891250
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
NCT06184399
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
NCT07145736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ivermectin
Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
Ivermectin
Ivermectin treatment
Standard of care
Standard of care treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivermectin
Ivermectin treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant and lactating mothers.
* Patients with cardiac problems.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
sherief Abd-Elsalam, Ass. Prof.
Role: PRINCIPAL_INVESTIGATOR
ass. Prof. Tropical Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
tanta covid treatment
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.